The next big thing for global Pharma - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

The next big thing for global Pharma

Oct 15, 2009

Emerging economies have been garnering a lot of interest of late as far as investments are concerned. Not only are the developed economies mired in a recession but the prospects also do not look too enthusing in the near future atleast. In stark contrast, emerging economies led by China and India are expected to post strong growth rates, a phenomenon which will be witnessed in the global pharmaceutical industry as well. Thus, in this article, we shall take a look at what is driving the growth of branded generics in these emerging markets. Domestic pharma's branded focus

Indian pharma companies were at the forefront in capitalising on the branded generics opportunity. As a result, their exports strategy not only revolved around selling generic medicines in the developed nations of the US and Europe but also in the semi or less regulated markets of Asia, Africa, Russia and the CIS. The latter especially were lucrative because generic medicines there can be branded and hence pushed through doctors. This could not be done in the US and Europe, which are heavily regulated. Here, generic medicines cannot be branded unless companies can show that their versions are more effective due to superior technology or a superior delivery mechanism. However, in the semi or less regulated markets, generics can be branded just like they are in India. But since they are not subject to price control as in India, the revenue and profit potential is that much higher.

Domestic companies such as Ranbaxy, Dr.Reddy's, Sun Pharma, Glenmark, Lupin, Cadila and the like are looking to enhance their presence in these regions especially when the US and European generics markets in recent times have been marred by intense competition and price erosion.

Global innovators jumping the bandwagon

Another breed of pharma companies have also realized the potential of branded generics and are looking to grab a slice of the branded generics pie. We are talking about the global innovators such as Pfizer Inc., GSK Plc, Sanofi-Aventis and the like, which previously focused on developing patented drugs. There are various reasons for wanting to dabble in generics as well. First is that their own research pipelines are drying up with not much to show for the amount of money invested in R&D. Secondly, many of their blockbusters are going off patent which would mean a huge drop in sales and profits. Thirdly, governments across the world are looking to cut healthcare costs by encouraging the use of generics. Little wonder than that Big Pharma which hitherto was averse to generics, is now finding itself joining hands with Indian generic players to foray into emerging markets. Case in point would be Pfizer Inc.'s partnership with Aurobindo Pharma and GSK Pharma's alliance with Dr.Reddy's amongst others.

Going forward...

We believe that branded generics will play an important role in driving the growth of the global pharmaceutical market. This is not to say that the US generics market will not witness growth as there are many patent expiries on the anvil. But because margins in the US are low, the emerging markets will form an important business for domestic pharma companies. As far as the global pharma markets are concerned, while the US pharma market is projected to register a decline of 1%-2% in 2009, the top five European markets (France Germany, the UK, Italy and Spain) are forecast to grow at 3%-4% in 2009.

This means that emerging markets (including India and China) will be the next frontier and these markets, which logged in a healthy growth of 12% in 2008, are expected to grow collectively at 13% to 16% up to 2013. Infact, the seven emerging markets (China, Brazil, India, South Korea, Mexico, Turkey and Russia) are expected to contribute 40% to the global market growth from 2009 to 2013 (Source: Dr.Reddy's annual report). Thus, akin to other industries, the pharma industry in the emerging markets hold huge potential and Indian pharma companies which are firmly entrenched in these markets stand to benefit immensely from the same.

Equitymaster requests your view! Post a comment on "The next big thing for global Pharma". Click here!

1 Responses to "The next big thing for global Pharma"

santushta

Oct 28, 2009

I have nt at received Midcapselect recommendatio for this wednsday 28/10/09

Like 
  
Equitymaster requests your view! Post a comment on "The next big thing for global Pharma". Click here!

More Views on News

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Dec 2, 2021 11:41 AM

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS